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BACKGROUND: Previously we demonstrated that an mRNA signature reflecting cellular proliferation had strong prognostic value.
As clinical applicability of signatures can be controversial, we sought to improve our marker’s clinical utility by validating its biological
relevance, reproducibility in independent data sets and applicability using an independent technique.
METHODS: To facilitate signature evaluation with quantitative PCR (qPCR) a novel computational procedure was used to reduce the
number of signature genes without significant information loss. These genes were validated in different human cancer cell lines upon
serum starvation and in a 168 xenografts panel. Analyses were then extended to breast cancer and non-small-cell lung cancer
(NSCLC) patient cohorts.
RESULTS: Expression of the qPCR-based signature was dramatically decreased under starvation conditions and inversely correlated
with tumour volume doubling time in xenografts. The signature validated in breast cancer (hazard ratio (HR)¼ 1.63, Po0.001,
n¼ 1820) and NSCLC adenocarcinoma (HR¼ 1.64, Po0.001, n¼ 639) microarray data sets. Lastly, qPCR in a node-negative,
non-adjuvantly treated breast cancer cohort (n¼ 129) showed that patients assigned to the high-proliferation group had worse
disease-free survival (HR¼ 2.25, Po0.05).
CONCLUSION: We have developed and validated a qPCR-based proliferation signature. This test might be used in the clinic to select
(early-stage) patients for specific treatments that target proliferation.
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Over the last decade, gene expression microarray technology has
had a profound impact on cancer research. The ability to analyse
the expression of thousands of genes in a single experiment has
been systematically used to derive prognostic and predictive
markers for many cancer types (Shedden et al, 2008; Sotiriou and
Pusztai, 2009; Gomez-Raposo et al, 2010; Oberthuer et al, 2010).
Numerous of these ‘signatures’ show good prognostic power, but
surprisingly gene-wise overlap between them has been minimal
(Ein-Dor et al, 2006; Fan et al, 2006; Chen et al, 2007; Lau et al,
2007), which increases the difficulty of introducing microarrays
in clinical practice. Moreover, studies comparing data originating
from different microarray platforms have reported poor inter-platform
correlations (Kuo et al, 2002; Tan et al, 2003). Nevertheless, multiple
studies in breast and non-small-cell lung cancer (NSCLC) have
shown that most of these signatures exhibit similar prognostic
performance and identify identical patients (Fan et al, 2006;
Haibe-Kains et al, 2008). These data suggest that, although gene-
wise overlap is small, the signatures track common underlying
biology that determine patient outcome. Among others, Weigelt
et al (2010) have suggested that proliferation genes drive
the prognostic power of these signatures (Whitfield et al, 2006;
Desmedt et al, 2008; Haibe-Kains et al, 2008). A large meta-
analysis by Wirapati et al (2008) supports this concept.
To determine if this result could be clinically useful, we
previously developed a signature based on 104 proliferation genes
(Starmans et al, 2008). This signature was derived from two
in vitro gene expression data sets. Genes were selected that showed
a cycling pattern after synchronisation in one data set and
responded to serum stimulation in the other. Our proliferation
signature exhibited strong prognostic power in several large
transcriptome data sets representing different cancer types
(Starmans et al, 2008). Further, the proliferation signature and
multiple other signatures identified similar patients as having good
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or poor prognosis (Starmans et al, 2008). These results sub-
stantiate the hypothesis that many published signatures act as
surrogates of proliferation.
The clinical applicability of gene expression signatures remains
controversial; studies seem to lack consistency and external
validation is not straightforward (Michiels et al, 2005; Ein-Dor
et al, 2006; Dupuy and Simon, 2007; Boulesteix and Slawski, 2009;
Boutros et al, 2010; Subramanian and Simon, 2010). Many gene
expression signatures were developed since the introduction of
gene expression microarray technology, however, so far only in
breast cancer two prognostic gene profiles are tested in large
prospective trials (Bogaerts et al, 2006; Sparano, 2006; Wirapati
et al, 2008; Weigelt et al, 2010). The dimensionality of gene
expression microarrays makes statistical analysis complex, and
large numbers of samples are required for reproducible results
(Zien et al, 2003; Ein-Dor et al, 2006). An approach to only
evaluate a select number of transcripts may therefore provide an
efficient alternative to high-throughput expression profiling. The
use of a PCR-based test to evaluate the proliferation signature
would assist in the application to a clinical setting (Zhou et al,
2010). Furthermore, a PCR-based technique does not necessitate
the availability of fresh-frozen tissue, whereas this is recommended
for gene expression microarrays (Tumour Analysis Best Practices
Working Group, 2004). Many more samples might thus be
available to validate classifiers with a PCR-based technique.
Initially, we examined whether it was possible to reduce the
number of genes in the proliferation signature, without deteriorat-
ing its prognostic value. The original signature consisted of 104
genes, and so reducing this number would make data collection,
analysis and transfer to a PCR-based approach simpler and more
transparent. To further facilitate translation of this reduced
proliferation signature to a PCR-platform a series of in vitro and
ex vivo validation experiments were performed. We reduced the
proliferation signature to 10 genes and validated it in 1820 breast
cancer and 862 NSCLC patients. Lastly, the reduced proliferation
signature was applied to another independent, 129-patient breast
cancer cohort with qPCR to demonstrate clinical utility.
MATERIALS AND METHODS
Gene size reduction
In our original study (Starmans et al, 2008) we developed a
104-gene proliferation signature and evaluated it in five different
microarray data sets representing breast, lung and renal cancers
(Beer et al, 2002; van de Vijver et al, 2002; Miller et al, 2005; Wang
et al, 2005; Zhao et al, 2006). To reduce the size of the signature,
each gene was tested for its univariate prognostic value in each
data set. This was for disease-specific (Miller et al, 2005; Zhao et al,
2006), metastasis-free (Wang et al, 2005) or overall (Beer et al,
2002; van de Vijver et al, 2002) survival, depending on what was
reported for the data set. Only genes that had fewer than 25%
missing values were included. Expression of each gene was used as
a continuous variable as input for receiver operator curve (ROC)
analysis. Genes were ranked within each data set by the area under
the ROC (Supplementary Data File S1), and then subjected to a
rank-based filtering. The filtering criteria were dependent on the
number of data sets that included a certain gene, and were:
 Present in 1/5 data sets: discard the gene
 Present in 2/5 data sets: select when ranked in top 20 for both
data sets
 Present in 3/5 data sets: select when ranked in top 20 in all three
data sets
 Present in 4/5 data sets: select when ranked in top 20 in 3 out of
4 data sets
 Present in 5/5 data sets: select when ranked in the top 20 in 4 out
of 5 data sets
Quantitative PCR
RNA was reverse-transcribed using I-script (Bio-Rad, Veenendaal,
The Netherlands) and quantitative PCR was performed in ABI 7500
(Applied Biosystems, Bleiswijk, The Netherlands). Gene abundance
was detected using power SYBR Green I (Applied Biosystems).
Primer sequences are provided in Supplementary Data File S2.
Relative abundance of every gene per sample (Xgene, sample) was
calculated using standard curves and normalisation to 18S rRNA
signal (Equation 1). This was followed by median scaling per gene
for each data set (Barsyte-Lovejoy et al, 2006).
Xgene; sample¼
CTgene;sample
slopegene
 cT18S;sample
slope18S
ð1Þ
A multi-gene signature score was subsequently calculated for the
reduced proliferation signature as follows:
Score¼
XN
n¼ 1
geneexpr;n ð2Þ
In which N is the number of genes in the multi-gene marker.
The parameter geneexpr,n for a sample equals the value 1 if the
sample has a level of gene n above the median for all samples in
the data set and  1 otherwise. All data analyses were performed
in R (v2.12.1).
In vitro validation
To validate the involvement in proliferation of the genes in the
reduced signature, serum starvation experiments were performed
in five cancer cell lines (MCF7, HeLa, HT-29, U-2 OS and DU145).
Cells were grown either in normal serum containing medium
(10% foetal bovine serum, FBS), the control situation, or in low
serum containing medium (0.1% FBS, starvation condition) for
48 h. RNA was isolated for both conditions for three biological
replicates. The multi-gene signature score (Equation 2) was calcu-
lated for each sample. Scores were then compared between normal
and serum starvation conditions with a two sample two-tailed
unpaired Student’s t-test (R v2.12.1).
Ex vivo validation with qPCR
A large set of xenografts (n¼ 168) was used to assess whether it is
feasible to evaluate the reduced proliferation signature in tumour
material. Material was isolated from xenografts grown from
different cancer cell lines (HeLa, HT-29, U-87, LS 174T, HCT 116
and Hep G2) obtained from previous studies in which tumour
volume doubling times (VDTs) were calculated (Oostendorp et al,
2008; Dubois et al, 2009a, b; Rouschop et al, 2010). The multi-gene
signature score (equation 2) was calculated and used to median
dichotomise the xenograft samples. Differences in tumour VDTs
were then assessed between the two groups with a two sample two-
tailed unpaired Student’s t-test (R v2.12.1).
Validation in independent microarray data sets
The reduced proliferation signature was further validated in
independent public mRNA abundance data sets. Several breast
cancer (Pawitan et al, 2005; Bild et al, 2006; Chin et al, 2006;
Sotiriou et al, 2006; Desmedt et al, 2007; Loi et al, 2008; Bos et al,
2009; Zhang et al, 2009; Li et al, 2010; Sabatier et al, 2010;
Symmans et al, 2010) and NSCLC (Bhattacharjee et al, 2001; Bild
et al, 2006; Raponi et al, 2006; Shedden et al, 2008; Lu et al, 2010)
data sets were used to assess the prognostic power of the reduced
proliferation signature. For NSCLC the data sets reported on
adenocarcinoma and/or squamous cell carcinoma. Considering
these are completely different disease types, separate analyses
were performed per subgroup. When overall survival was provided
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this was used as end point, otherwise disease-specific survival
(or the closest variant available) was used. All data sets used
Affymetrix microarrays, which were normalised using the RMA
algorithm (Irizarry et al, 2003) (R packages: affy v1.26.1) combined
with updated ProbeSet annotations (Dai et al, 2005b) (R packages
v12.1.0: hgu95av2hsentrezgcdf, hgu133ahsentrezgcdf, hgu133bh-
sentrezgcdf and hgu133plus2hsentrezgcdf). Genes were matched
across data sets based on Entrez Gene IDs. Median scaling and
housekeeping gene normalisation (to the geometric mean of
ACTB, BAT1, B2M and TBP levels) was performed (Barsyte-
Lovejoy et al, 2006). The multi-gene signature score (Equation 2)
was used to median dichotomise the patients in a data set.
Patients predicted as having good or poor prognosis in any of
the data sets were pooled into different groups. This was done
for the breast cancer and lung cancer data sets separately. Prognostic
performance of the reduced proliferation signature was evaluated by
Cox proportional hazard ratio (HR) modelling followed by the Wald
test (R survival package v2.36-2). For breast cancer 15-year survival
was used as end point and 5-year survival for NSCLC.
Validation in independent patient cohort
The reduced proliferation signature was evaluated using qPCR
in a breast cancer patient cohort of the breast tumour bank of
the Radboud University Nijmegen Medical Centre (Nijmegen,
The Netherlands) as described previously (Span et al, 2004).
Patients underwent modified radical mastectomy or a breast-
conserving lumpectomy between November 1987 and December
1997. Postoperative radiotherapy was administered, to the breast
after an incomplete resection or after breast-conserving treat-
ment, or to the parasternal lymph nodes when the tumour was
medially localised. Patients did not receive (neo-) adjuvant
systemic therapy according to the standard treatment protocol
at the time. RNA was available from 129 lymph node-negative
breast cancer patients.
Quantitative PCR was carried out to evaluate the reduced
proliferation signature in this patient cohort. Subsequently the
multi-gene signature score (Equation 2) was calculated and
patients were either assigned to the low- or high-expression
group. Patients in the low expression group are predicted to have
good prognosis, whereas patients in the high-expression group are
predicted to have poor prognosis. Disease-free survival was used as
follow-up end point. Univariate and multi-variate Cox propor-
tional HR modelling followed by the Wald test was used to evaluate
the reduced proliferation signature (R survival package version
2.36-2). For a subgroup of the cohort histological grade was
unknown, median imputation was applied for those patients
(R e1071 package v1.5-24). Moreover, multi-variate models
with and without the signature were evaluated with the C-index
(R survival package v2.36-2).
RESULTS
To reduce the number of genes in the proliferation signature,
genes were ranked according to their individual prognostic
power in each of the five data sets used in the original study
(Supplementary Data File S1) (Starmans et al, 2008). After filtering
and gene ranking, the final reduced proliferation signature
consisted of 10 genes, which is a reduction of 90% (Table 1).
The original basis of the proliferation signature was in gene
expression studies carried out in vitro. To ensure that the
remaining genes accurately reflect proliferation status per se,
especially when assessed by qPCR, we evaluated the reduced
signature both in vitro and ex vivo. First, five different cancer cell
lines (MCF7, HeLa, HT-29, U-2 OS and DU145) were cultured in
either normal or serum-starved conditions. Figure 1A shows that
expression of the reduced proliferation signature was significantly
lower upon serum starvation compared with control growing
conditions (P¼ 1.52 10 11, t-test). Individual genes showed a
similar pattern (Supplementary Figure S1).
Table 1 The reduced proliferation signature genes
Gene
symbol
Entrez
gene ID Name
BUB1B 701 Budding uninhibited by benzimidazoles 1 homologue
beta (yeast)
CCNA2 890 Cyclin A2
CCNB2 9133 Cyclin B2
FANCI 55215 Fanconi anaemia, complementation group I
MELK 9833 Maternal embryonic leucine zipper kinase
NCAPH 23397 Non-SMC condensing I complex, subunit H
RRM2 6241 Ribonucleotide reductase M2
SKA3 221150 Spindle and kinetochore-associated complex 3
UBE2C 11065 Ubiquitin-conjugating enzyme E2C
UBE2T 29089 Ubiquitin-conjugating enzyme E2T (putative)
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Figure 1 In vitro validation: difference in reduced proliferation score in
normal vs starvation conditions (A). Ex vivo validation: Corresponding volume
doubling times (VDTs) for a xenograft data set (n¼ 168) dichotomized with
the reduced proliferation signature in a low and high-proliferation group (B).
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We then assessed expression of the 10 genes in a panel of
tumour xenografts with known VDTs (Oostendorp et al, 2008;
Dubois et al, 2009a, b; Rouschop et al, 2010) originating from
different cancer cell lines. Xenografts were assigned to either the
low- or high-proliferation group based on expression of the
reduced proliferation signature. Although proliferation rate is
not expected to be the only parameter, which influences gross
tumour growth (e.g., rates of cell turnover are also important),
we hypothesised that VDTs in the group with high proli-
feration should be reduced compared with xenografts with
low proliferation. Figure 1B confirms this hypothesis: a signi-
ficant difference in VDTs between high- and low-proliferation
signature xenografts was observed (P¼ 5.32 10 6, fold-change
VDTlow proliferation/VDThigh proliferation
 ¼ 1.60; t-test).
To demonstrate its prognostic power, the reduced signature was
evaluated in two large gene expression-based meta-data sets of
1820 breast and 862 NSCLC patients. None of these data sets were
included in the original study; all were fully independent. Patients
were stratified based on the reduced proliferation signature and
Cox proportional hazards modelling was used to assess perfor-
mance. Patient classification with the reduced proliferation
signature could stratify breast (Figure 2A: HR¼ 1.63; 95% CI:
1.39–1.92; P¼ 1.42 10 9 Wald test) and NSCLC patients
(Figure 2B: HR¼ 1.35; 95% CI: 1.10–1.66; P¼ 34.47 10 3 Wald
test) into groups with distinct prognostic profiles. High expression
of the reduced proliferation signature correlated with poor survival
in all patient groups. For NSCLC subgroup analyses were performed
for the adenocarcinoma and squamous cell carcinoma patient
groups, for these are significantly distinct disease states. Non-small-
cell lung cancer adenocarcinoma patients could be grouped into
cohorts with significantly different survival properties (Figure 2C:
HR¼ 1.64; 95% CI: 1.30–2.06; P¼ 3.01 10 5 Wald test). However,
in the squamous cell carcinoma cohort the reduced proliferation
signature had no prognostic power (Figure 2D: HR¼ 0.66; 95% CI:
0.41–1.04; P¼ 7.14 10 2 Wald test). In Supplementary Figures S2
and S3 Kaplan–Meier survival curves for the individual data sets are
provided. These data indicate that reduction of the proliferation
signature was successful; the reduced signature could stratify
patients into groups with significant differences in survival.
To confirm the prognostic performance of the reduced
proliferation signature when evaluated by qPCR, we tested its
performance in a further independent cohort of 129 lymph node-
negative breast cancer patients. This patient group is distinct from
those used for model development and from those in the meta-data
set analysis. Table 2 displays patient and treatment characteristics.
The reduced proliferation signature stratified the cohort into
groups predicted to have either good (low proliferation) or poor
prognosis (high proliferation). Figure 3A shows that the patient
group predicted to have poor prognosis had significantly worse
disease-specific survival than the good prognosis group
(HR¼ 2.25; 95% CI: 1.01–4.99; P¼ 4.60 10 2 Wald test). The
majority of this cohort were stage I patients, therefore a subgroup
analysis was performed. The reduced proliferation signature could
stratify stage I patients in two groups with highly significant
differences in prognosis (Figure 3B: HR¼ 5.92; 95% CI: 1.62–21.59;
P¼ 7.03 10 3 Wald test). To investigate whether the signature’s
prognostic power was independent of other clinical factors multi-
variate Cox proportional HR modelling was used. In the whole-
patient cohort the reduced signature performed comparable to stage
(Supplementary Table S1), however, it did, like the other factors
included, not reach statistical significance (HR¼ 1.73; 95% CI:
0.73–4.12; P¼ 0.215 Wald test). In stage I patients the reduced
proliferation signature was the top prognostic factor (Table 3,
HR¼ 7.23; 95% CI: 1.65–31.95; P¼ 8.57 10 3 Wald test).
1.00
0.75
Fr
a
ct
io
n 
of
 c
oh
or
t
Fr
a
ct
io
n 
of
 c
oh
or
t
Fr
a
ct
io
n 
of
 c
oh
or
t
Fr
a
ct
io
n 
of
 c
oh
or
t
0.50
0.25
HR: 1.63 (1.39–1.92) HR: 1.35 (1.10–1.66)
HR: 0.66 (0.41–1.04)HR: 1.64 (1.30–2.06)
P : 3.01 × 10–5
0.00
1.00
0.75
0.50
0.25
0.00
1.00
0.75
0.50
0.25
0.00
1.00
0.75
0.50
0.25
0.00
0
Number at risk
Low
High
Number at risk
Low
High
Number at risk
Low
High
Number at risk
Low
High
978
842 606
797 546
334
305 251
302 262 218 96 76 55 41 30
3044506880104
115
153 114
169 113
92198
359 168
284 118
76
40
27
453
409 331
402 341
267
276
204 157
214 146
121
0 1 2 3 4 53 6 9 12 15
Time (years)
Sig = good
Sig = poor
Sig = good
Sig = poor
Sig = good
Sig = poor
Sig = good
Sig = poor
Time (years)
0 1 2 3 4 5
Time (years)
0 1 2 3 4 5
Time (years)
P : 0.003
P : 0.07
P : 1.42 × 10–9
Figure 2 Validation of the reduced proliferation signature in a breast cancer (A) and non-small-cell lung cancer (B) meta-data set, for NSCLC a subgroup
analysis was performed for adenocarcinoma (C) and squamous cell carcinoma (D): patients with high proliferation have significant worse survival than
patients in the low proliferation group. Abbreviations: HR¼ hazard ratio; P¼ P-value Wald test.
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C-indexes for multi-variate Cox proportional HR models of clinical
parameters with and without the reduced proliferation signature
were calculated. Both in the whole cohort and stage I patient group
adding the signature increased prognostic power, in the stage I
patient group the signature alone outperformed the model
comprising clinical parameters (Supplementary Table S2).
DISCUSSION
We previously reported a microarray-based proliferation signature
with high-prognostic power in several large microarray data sets
encompassing different cancer types. Here, we successfully
reduced the number of genes in the proliferation signature to a
more appropriate scale for low-throughput technologies. This
could greatly facilitate the translation into a clinically applicable
test (Zhou et al, 2010). In two large independent gene expression
meta-data sets for breast and NSCLC the reduced signature
separated the patients into groups with significant distinct survival
properties.
A subgroup analysis for the NSCLC cohort showed high-
prognostic power in adenocarcinoma patients, whereas in
squamous cell carcinoma patients no prognostic power was
observed. Earlier studies have shown similar data for other
measures of proliferation; high proliferation was significantly
associated with incidence of metastasis and worse survival in
adenocarcinomas, but not in squamous cell carcinomas (Komaki
et al, 1996; Hommura et al, 2000). Recapitulating decreasing the
number of signature genes resulted in a new marker with high
performance across different cancer types.
Several genes in the signature have previously been implicated
in cancer outcome (Glinsky, 2006; Whitfield et al, 2006; Ryu et al,
2007; Hao et al, 2008; Marie et al, 2008). UBE2C (ubiquitin-
conjugating enzyme E2C) expression was correlated with malig-
nant progression in thyroid carcinomas and demonstrated
Table 2 Baseline demographics of breast cancer patient cohort in
low and high-risk group assessed with the reduced proliferation signature
(full characteristics were represented previously (Span et al, 2004))
Factor
All patients
(N¼ 129)
Low risk
(N¼ 61)
High risk
(N¼ 68) Pa
Surgery 0.371
Mastectomy 55 23 32
Lumpectomy 74 38 36
Radiotherapy 0.935
Yes 84 39 45
No 45 22 23
Stage of disease 0.004
I 78 46 32
II 48 14 34
III 3 1 2
Gradeb 0.142c
G1 9 5 4
G2 48 25 23
G3 40 13 27
Not recorded 32 18 14
Histological type 0.017
Ductal 90 45 45
Lobular 19 12 7
Other 20 4 16
Menopausal 0.928
Pre 26 13 13
Post 103 48 55
Treatment 0.121
Lumpectomyþ radiotherapy 74 38 36
Mastectomy 44 21 23
Mastectomyþ radiotherapy 11 2 9
aP-value w2-test. bGrading was performed according to Bloom and Richardson, by the
method modified by Elston and Ellis (1991). cWithout including those with missing or
unknown values.
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Figure 3 Validation of the reduced proliferation signature with qPCR in a breast cancer patient cohort; high-prognostic power is achieved (A), which is
most pronounced in the stage I patient group (B). Abbreviations: HR¼ hazard ratio; P¼ P-value Wald test.
Table 3 Results multi-variate Cox regression model in stage I patient
group (78 patients)
Factor HR 95% CI P*
Reduced proliferation signature 7.23 1.65–31.59 0.009
Grade (vs grade 1)
Grade 2 0.79 0.14–4.36 0.783
Grade 3 0.17 0.021–1.36 0.095
Histological type (vs ductal)
Histological type lobular 0 0.00–inf 0.998
Histological type other 2.02 0.54–7.64 0.298
Age 0.99 0.90–1.11 0.992
Menopausal (pre vs post) 0.95 0.061–14.71 0.970
Treatment (vs lumpectomyþ radiotherapy)
Mastectomy 2.99 0.79–11.26 0.106
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio. *P-value Wald test.
Multi-tumour-type proliferation signature
MHW Starmans et al
512
British Journal of Cancer (2012) 107(3), 508 – 515 & 2012 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
stic
s
prognostic power in ovarian cancer (Pallante et al, 2005;
Berlingieri et al, 2007; van Ree et al, 2010), in which high
expression was associated with worse survival. Overexpression of
RRM2 (ribonucleotide reductase M2) showed association with
chemotherapy resistance (Boukovinas et al, 2008). Furthermore, a
large fraction of the published gene expression signatures include
clusters of proliferation-associated genes and several of the
reduced proliferation genes are represented in these clusters
(Whitfield et al, 2002; Dai et al, 2005a; Shedden et al, 2008; Weigelt
et al, 2010).
As a last step the reduced proliferation signature was evaluated
with qPCR in an independent breast cancer patient cohort. This
patient group consisted entirely of patients without axillary lymph
node metastases, and who did not receive systemic adjuvant
therapy, making it possible to distinguish a pure prognostic value
of the proliferation signature. The reduced proliferation signature
stratified patients into groups with different survival properties
and showed high-prognostic power especially in stage I patients.
A high disease-specific survival was observed in the stage I patients
identified as having low risk. This suggests the reduced prolifera-
tion signature might be useful in identifying high-risk stage I
breast cancer patients that could benefit from additional therapy
like chemo-radiation or accelerated radiotherapy, whereas the low
risk group would not.
Currently two large prospective trials have been started to
address the predictive performance of two gene expression
signatures in early breast cancer (Bogaerts et al, 2006; Sparano,
2006). Both these signatures include a subset of proliferation genes
and several meta-analyses show evidence that the prognostic value
of these signatures is mostly attributed to this process (Wirapati
et al, 2008; Weigelt et al, 2010). Therefore, a signature reflecting
merely proliferation could make its interpretation easier. Further-
more the prognostic power of the reduced proliferation signature
was not limited to breast cancer; it also had a high performance in
a NSCLC adenocarcinoma meta-data set.
Thus, we here show that the array-based proliferation signature
could be reduced to 10 genes. This reduced proliferation signature
can be applied in small-tissue samples, including possibly FFPE
material, adding to its clinical applicability. The pure prognostic
power of the signature was validated in an independent breast
cancer patient cohort, where it was shown to be particularly useful
to select patients that would benefit from more aggressive therapy.
To fully grasp the potential prognostic or predictive role of the
signature it further should be tested in prospective trials and
translated from a relative to an absolute measure.
ACKNOWLEDGEMENTS
This work was supported by the Centre for Translational
Molecular Medicine (www.ctmm.nl) (AIRFORCE Project Ref.
030-103) and the Ontario Institute for Cancer Research through
funding provided by the Government of Ontario to PCB.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
REFERENCES
Barsyte-Lovejoy D, Lau SK, Boutros PC, Khosravi F, Jurisica I, Andrulis IL,
Tsao MS, Penn LZ (2006) The c-Myc oncogene directly induces the H19
noncoding RNA by allele-specific binding to potentiate tumorigenesis.
Cancer Res 66: 5330–5337
Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L,
Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S,
Taylor JM, Iannettoni MD, Orringer MB, Hanash S (2002) Gene-
expression profiles predict survival of patients with lung adenocarci-
noma. Nat Med 8: 816–824
Berlingieri MT, Pallante P, Guida M, Nappi C, Masciullo V, Scambia G,
Ferraro A, Leone V, Sboner A, Barbareschi M, Ferro A, Troncone G,
Fusco A (2007) UbcH10 expression may be a useful tool in the prognosis
of ovarian carcinomas. Oncogene 26: 2136–2140
Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C,
Beheshti J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, Lander ES,
Wong W, Johnson BE, Golub TR, Sugarbaker DJ, Meyerson M (2001)
Classification of human lung carcinomas by mRNA expression profiling
reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98:
13790–13795
Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D,
Lancaster JM, Berchuck A, Olson Jr. JA, Marks JR, Dressman HK, West M,
Nevins JR (2006) Oncogenic pathway signatures in human cancers as a
guide to targeted therapies. Nature 439: 353–357
Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J,
Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van ’t Veer LJ,
Piccart M (2006) Gene signature evaluation as a prognostic tool:
challenges in the design of the MINDACT trial. Nat Clin Pract Oncol
3: 540–551
Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van
de Vijver MJ, Gerald WL, Foekens JA, Massague J (2009) Genes that
mediate breast cancer metastasis to the brain. Nature 459: 1005–1009
Boukovinas I, Papadaki C, Mendez P, Taron M, Mavroudis D, Koutsopoulos A,
Sanchez-Ronco M, Sanchez JJ, Trypaki M, Staphopoulos E, Georgoulias V,
Rosell R, Souglakos J (2008) Tumor BRCA1, RRM1 and RRM2 mRNA
expression levels and clinical response to first-line gemcitabine plus
docetaxel in non-small-cell lung cancer patients. PLoS One 3: e3695
Boulesteix AL, Slawski M (2009) Stability and aggregation of ranked gene
lists. Brief Bioinform 10: 556–568
Boutros PC, Pintilie M, John T, Starmans MH, Der SD, Shepherd FA,
Tsao MS, Jurisica I (2010) Re: Gene Expression-Based Prognostic
Signatures in Lung Cancer: Ready for Clinical Use? J Natl Cancer Inst
102(21): 1677–1678
Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL,
Wang CH, Terng HJ, Kao SF, Chan WK, Li HN, Liu CC, Singh S,
Chen WJ, Chen JJ, Yang PC (2007) A five-gene signature and clinical
outcome in non-small-cell lung cancer. N Engl J Med 356: 11–20
Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL,
Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T,
Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM,
Esserman L, Albertson DG, Waldman FM, Gray JW (2006) Genomic and
transcriptional aberrations linked to breast cancer pathophysiologies.
Cancer Cell 10: 529–541
Dai H, van’t Veer L, Lamb J, He YD, Mao M, Fine BM, Bernards R, van de
Vijver M, Deutsch P, Sachs A, Stoughton R, Friend S (2005a) A cell
proliferation signature is a marker of extremely poor outcome in a
subpopulation of breast cancer patients. Cancer Res 65: 4059–4066
Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers
RM, Speed TP, Akil H, Watson SJ, Meng F (2005b) Evolving gene/
transcript definitions significantly alter the interpretation of GeneChip
data. Nucleic Acids Res 33: e175
Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi
G, Delorenzi M, Piccart M, Sotiriou C (2008) Biological processes
associated with breast cancer clinical outcome depend on the molecular
subtypes. Clin Cancer Res 14: 5158–5165
Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B,
Viale G, Delorenzi M, Zhang Y, d’Assignies MS, Bergh J, Lidereau R,
Ellis P, Harris AL, Klijn JG, Foekens JA, Cardoso F, Piccart MJ,
Buyse M, Sotiriou C (2007) Strong time dependence of the 76-gene
prognostic signature for node-negative breast cancer patients in the
TRANSBIG multicenter independent validation series. Clin Cancer Res
13: 3207–3214
Dubois L, Lieuwes NG, Maresca A, Thiry A, Supuran CT, Scozzafava A,
Wouters BG, Lambin P (2009a) Imaging of CA IX with fluorescent
labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in
a xenograft tumour model. Radiother Oncol 92: 423–428
Dubois L, Magagnin MG, Cleven AH, Weppler SA, Grenacher B, Landuyt
W, Lieuwes N, Lambin P, Gorr TA, Koritzinsky M, Wouters BG (2009b)
Inhibition of 4E-BP1 sensitizes U87 glioblastoma xenograft tumors to
irradiation by decreasing hypoxia tolerance. Int J Radiat Oncol Biol Phys
73: 1219–1227
Multi-tumour-type proliferation signature
MHW Starmans et al
513
& 2012 Cancer Research UK British Journal of Cancer (2012) 107(3), 508 – 515
M
o
le
c
u
la
r
D
ia
g
n
o
st
ic
s
Dupuy A, Simon RM (2007) Critical review of published microarray studies
for cancer outcome and guidelines on statistical analysis and reporting.
J Natl Cancer Inst 99: 147–157
Ein-Dor L, Zuk O, Domany E (2006) Thousands of samples are needed to
generate a robust gene list for predicting outcome in cancer. Proc Natl
Acad Sci USA 103: 5923–5928
Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer.
I. The value of histological grade in breast cancer: experience from a
large study with long-term follow-up. Histopathology 19: 403–410
Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van’t Veer LJ,
Perou CM (2006) Concordance among gene-expression-based predictors
for breast cancer. N Engl J Med 355: 560–569
Glinsky GV (2006) Genomic models of metastatic cancer: functional
analysis of death-from-cancer signature genes reveals aneuploid,
anoikis-resistant, metastasis-enabling phenotype with altered cell cycle
control and activated Polycomb Group (PcG) protein chromatin
silencing pathway. Cell Cycle 5: 1208–1216
Gomez-Raposo C, Mendiola M, Barriuso J, Hardisson D, Redondo A (2010)
Molecular characterization of ovarian cancer by gene-expression
profiling. Gynecol Oncol 118: 88–92
Haibe-Kains B, Desmedt C, Sotiriou C, Bontempi G (2008) A comparative
study of survival models for breast cancer prognostication based on
microarray data: does a single gene beat them all? Bioinformatics 24:
2200–2208
Hao J, Xu A, Xie X, Tian T, Gao S, Xiao X, He D (2008) Elevated expression
of UBE2T in lung cancer tumors and cell lines. Tumour Biol 29: 195–203
Hommura F, Dosaka-Akita H, Mishina T, Nishi M, Kojima T, Hiroumi H,
Ogura S, Shimizu M, Katoh H, Kawakami Y (2000) Prognostic
significance of p27KIP1 protein and ki-67 growth fraction in non-small
cell lung cancers. Clin Cancer Res 6: 4073–4081
Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U,
Speed TP (2003) Exploration, normalization, and summaries of high
density oligonucleotide array probe level data. Biostatistics 4: 249–264
Komaki R, Fujii T, Perkins P, Ro JY, Allen PK, Mason KA, Mountain CF,
Milas L (1996) Apoptosis and mitosis as prognostic factors in
pathologically staged N1 nonsmall cell lung cancer. Int J Radiat Oncol
Biol Phys 36: 601–605
Kuo WP, Jenssen TK, Butte AJ, Ohno-Machado L, Kohane IS (2002)
Analysis of matched mRNA measurements from two different micro-
array technologies. Bioinformatics 18: 405–412
Lau SK, Boutros PC, Pintilie M, Blackhall FH, Zhu CQ, Strumpf D, Johnston
MR, Darling G, Keshavjee S, Waddell TK, Liu N, Lau D, Penn LZ,
Shepherd FA, Jurisica I, Der SD, Tsao MS (2007) Three-gene prognostic
classifier for early-stage non small-cell lung cancer. J Clin Oncol 25:
5562–5569
Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Desmedt C, Sotiriou C, Szallasi Z,
Iglehart JD, Richardson AL, Wang ZC (2010) Amplification of LAPTM4B
and YWHAZ contributes to chemotherapy resistance and recurrence of
breast cancer. Nat Med 16: 214–218
Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C,
Ellis P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EM, Jansen MP,
Foekens JA, Delorenzi M, Bontempi G, Piccart MJ, Sotiriou C (2008)
Predicting prognosis using molecular profiling in estrogen receptor-
positive breast cancer treated with tamoxifen. BMC Genomics 9: 239
Lu TP, Tsai MH, Lee JM, Hsu CP, Chen PC, Lin CW, Shih JY, Yang PC,
Hsiao CK, Lai LC, Chuang EY (2010) Identification of a novel biomarker,
SEMA5A, for non-small cell lung carcinoma in nonsmoking women.
Cancer Epidemiol Biomarkers Prev 19: 2590–2597
Marie SK, Okamoto OK, Uno M, Hasegawa AP, Oba-Shinjo SM, Cohen T,
Camargo AA, Kosoy A, Carlotti Jr. CG, Toledo S, Moreira-Filho CA,
Zago MA, Simpson AJ, Caballero OL (2008) Maternal embryonic leucine
zipper kinase transcript abundance correlates with malignancy grade in
human astrocytomas. Int J Cancer 122: 807–815
Michiels S, Koscielny S, Hill C (2005) Prediction of cancer outcome with
microarrays: a multiple random validation strategy. Lancet 365: 488–492
Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall
P, Klaar S, Liu ET, Bergh J (2005) An expression signature for p53 status
in human breast cancer predicts mutation status, transcriptional effects,
and patient survival. Proc Natl Acad Sci USA 102: 13550–13555
Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y,
Asgharzadeh S, Seeger R, Scaruffi P, Tonini GP, Janoueix-Lerosey I,
Delattre O, Schleiermacher G, Vandesompele J, Vermeulen J, Speleman F,
Noguera R, Piqueras M, Benard J, Valent A, Avigad S, Yaniv I, Weber A,
Christiansen H, Grundy RG, Schardt K, Schwab M, Eils R, Warnat P,
Kaderali L, Simon T, Decarolis B, Theissen J, Westermann F, Brors B,
Fischer M (2010) Prognostic impact of gene expression-based classifica-
tion for neuroblastoma. J Clin Oncol 28: 3506–3515
Oostendorp M, Douma K, Hackeng TM, Dirksen A, Post MJ, van Zandvoort
MA, Backes WH (2008) Quantitative molecular magnetic resonance
imaging of tumor angiogenesis using cNGR-labeled paramagnetic
quantum dots. Cancer Res 68: 7676–7683
Pallante P, Berlingieri MT, Troncone G, Kruhoffer M, Orntoft TF, Viglietto G,
Caleo A, Migliaccio I, Decaussin-Petrucci M, Santoro M, Palombini L,
Fusco A (2005) UbcH10 overexpression may represent a marker of
anaplastic thyroid carcinomas. Br J Cancer 93: 464–471
Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L,
Huang F, Klaar S, Liu ET, Miller L, Nordgren H, Ploner A, Sandelin K,
Shaw PM, Smeds J, Skoog L, Wedren S, Bergh J (2005) Gene expression
profiling spares early breast cancer patients from adjuvant therapy:
derived and validated in two population-based cohorts. Breast Cancer
Res 7: R953–R964
Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JM, Macdonald J, Thomas D,
Moskaluk C, Wang Y, Beer DG (2006) Gene expression signatures for
predicting prognosis of squamous cell and adenocarcinomas of the lung.
Cancer Res 66: 7466–7472
Rouschop KM, van den Beucken T, Dubois L, Niessen H, Bussink J,
Savelkouls K, Keulers T, Mujcic H, Landuyt W, Voncken JW, Lambin P,
van der Kogel AJ, Koritzinsky M, Wouters BG (2010) The unfolded
protein response protects human tumor cells during hypoxia through
regulation of the autophagy genes MAP1LC3B and ATG5. J Clin Invest
120: 127–141
Ryu B, Kim DS, Deluca AM, Alani RM (2007) Comprehensive expression
profiling of tumor cell lines identifies molecular signatures of melanoma
progression. PLoS One 2: e594
Sabatier R, Finetti P, Cervera N, Lambaudie E, Esterni B, Mamessier E,
Tallet A, Chabannon C, Extra JM, Jacquemier J, Viens P, Birnbaum D,
Bertucci F (2010) A gene expression signature identifies two prognostic
subgroups of basal breast cancer. Breast Cancer Res Treat 126(2):
407–420
Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL,
Eschrich S, Jurisica I, Giordano TJ, Misek DE, Chang AC, Zhu CQ,
Strumpf D, Hanash S, Shepherd FA, Ding K, Seymour L, Naoki K, Pennell
N, Weir B, Verhaak R, Ladd-Acosta C, Golub T, Gruidl M, Sharma A,
Szoke J, Zakowski M, Rusch V, Kris M, Viale A, Motoi N, Travis W,
Conley B, Seshan VE, Meyerson M, Kuick R, Dobbin KK, Lively T,
Jacobson JW, Beer DG (2008) Gene expression-based survival prediction
in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med
14: 822–827
Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N
Engl J Med 360: 790–800
Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P,
Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H,
Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M
(2006) Gene expression profiling in breast cancer: understanding the
molecular basis of histologic grade to improve prognosis. J Natl Cancer
Inst 98: 262–272
Span PN, Waanders E, Manders P, Heuvel JJ, Foekens JA, Watson MA, Beex
LV, Sweep FC (2004) Mammaglobin is associated with low-grade, steroid
receptor-positive breast tumors from postmenopausal patients, and has
independent prognostic value for relapse-free survival time. J Clin Oncol
22: 691–698
Sparano JA (2006) TAILORx: trial assigning individualized options for
treatment (Rx). Clin Breast Cancer 7: 347–350
Starmans MH, Krishnapuram B, Steck H, Horlings H, Nuyten DS, van de
Vijver MJ, Seigneuric R, Buffa FM, Harris AL, Wouters BG, Lambin P
(2008) Robust prognostic value of a knowledge-based proliferation
signature across large patient microarray studies spanning different
cancer types. Br J Cancer 99: 1884–1890
Subramanian J, Simon R (2010) Gene expression-based prognostic
signatures in lung cancer: ready for clinical use? J Natl Cancer Inst
102: 464–474
Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P,
Daxenbichler G, Desmedt C, Domont J, Marth C, Delaloge S, Bauernhofer T,
Valero V, Booser DJ, Hortobagyi GN, Pusztai L (2010) Genomic index
of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 28:
4111–4119
Tan PK, Downey TJ, Spitznagel Jr. EL, Xu P, Fu D, Dimitrov DS,
Lempicki RA, Raaka BM, Cam MC (2003) Evaluation of gene expression
measurements from commercial microarray platforms. Nucleic Acids Res
31: 5676–5684
Multi-tumour-type proliferation signature
MHW Starmans et al
514
British Journal of Cancer (2012) 107(3), 508 – 515 & 2012 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
stic
s
Tumor Analysis Best Practices Working Group (2004) Expression
profiling–best practices for data generation and interpretation in clinical
trials. Nat Rev Genet 5: 229–237
van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW,
Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D,
Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H,
Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-
expression signature as a predictor of survival in breast cancer. N Engl J
Med 347: 1999–2009
van Ree JH, Jeganathan KB, Malureanu L, van Deursen JM (2010)
Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10
causes chromosome missegregation and tumor formation. J Cell Biol
188: 83–100
Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D,
Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins
D, Foekens JA (2005) Gene-expression profiles to predict distant
metastasis of lymph-node-negative primary breast cancer. Lancet 365:
671–679
Weigelt B, Baehner FL, Reis-Filho JS (2010) The contribution of gene
expression profiling to breast cancer classification, prognostication and
prediction: a retrospective of the last decade. J Pathol 220: 263–280
Whitfield ML, George LK, Grant GD, Perou CM (2006) Common markers of
proliferation. Nat Rev Cancer 6: 99–106
Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE,
Matese JC, Perou CM, Hurt MM, Brown PO, Botstein D (2002)
Identification of genes periodically expressed in the human cell cycle
and their expression in tumors. Mol Biol Cell 13: 1977–2000
Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B,
Desmedt C, Ignatiadis M, Sengstag T, Schutz F, Goldstein DR, Piccart M,
Delorenzi M (2008) Meta-analysis of gene expression profiles in breast
cancer: toward a unified understanding of breast cancer subtyping and
prognosis signatures. Breast Cancer Res 10: R65
Zhang Y, Sieuwerts AM, McGreevy M, Casey G, Cufer T, Paradiso A,
Harbeck N, Span PN, Hicks DG, Crowe J, Tubbs RR, Budd GT, Lyons J,
Sweep FC, Schmitt M, Schittulli F, Golouh R, Talantov D, Wang Y,
Foekens JA (2009) The 76-gene signature defines high-risk patients that
benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat 116:
303–309
Zhao H, Ljungberg B, Grankvist K, Rasmuson T, Tibshirani R, Brooks JD
(2006) Gene expression profiling predicts survival in conventional renal
cell carcinoma. PLoS Med 3: e13
Zhou YH, Raj VR, Siegel E, Yu L (2010) Standardization of gene expression
quantification by absolute real-time qRT-PCR system using a single
standard for marker and reference genes. Biomark Insights 5: 79–85
Zien A, Fluck J, Zimmer R, Lengauer T (2003) Microarrays: how many do
you need? J Comput Biol 10: 653–667
This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the
license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.
Multi-tumour-type proliferation signature
MHW Starmans et al
515
& 2012 Cancer Research UK British Journal of Cancer (2012) 107(3), 508 – 515
M
o
le
c
u
la
r
D
ia
g
n
o
st
ic
s
